<DOC>
	<DOCNO>NCT01358812</DOCNO>
	<brief_summary>The GONO-FOLFOXIRI regimen demonstrate high activity efficacy compare FOLFIRI phase III trial . Panitumumab oxaliplatin- irinotecan-based doublet feasible associate improved activity KRAS codon 12-13 wild-type patient . BRAF RAS rare mutation suggest additional potential biomarkers anti-EGFR agent metastatic colo-rectal cancer . The present study aim demonstrate feasibility activity first-line combination GONO-FOLFOXIRI regimen Panitumumab molecularly select metastatic colo-rectal cancer patient .</brief_summary>
	<brief_title>FOLFOXIRI Plus Panitumumab In Kras Braf Wild-Type Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm colorectal adenocarcinoma ; Availability formalinfixed paraffin embed tumor block primary metastasis ; KRAS BRAF wildtype status primary colorectal cancer relate metastasis ; Unresectable measurable metastatic disease accord RECIST criterion ; Male female , age &gt; /= 18 year &lt; /= 75 year ; ECOG PS &lt; 2 age &lt; 71 year ; ECOG PS = 0 aged 7175 year ; Life expectancy 3 month ; Adequate haematological function : ANC ≥ 1.5 x 109/L ; platelet ≥ 100 x 109/L , Hb ≥ 9 g/dL ; Adequate liver function : serum bilirubin ≤ 1.5 x ULN ; alkaline phosphatase transaminases ≤ 2.5 x ULN ( case liver metastases &lt; 5 x ULN ) ; Serum creatinine ≤ 1.5 x ULN ; Previous adjuvant chemotherapy allow 12 month elapse end adjuvant therapy first relapse ; At least 6 week prior radiotherapy 4 week surgery ; Written inform consent experimental treatment pharmacogenomic analysis ; Magnesium ≥ low limit normal ; Calcium ≥ low limit normal . Prior palliative chemotherapy ; Prior treatment EGFR inhibitor ; Symptomatic peripheral neuropathy ≥ 2 grade NCICCTG criterion ; Presence history CNS metastasis ; Active uncontrolled infection ; active disseminate intravascular coagulation ; Past current history malignancy colorectal carcinoma , except curatively treat basal squamous cell carcinoma skin cancer situ carcinoma cervix ; Clinically significant cardiovascular disease , example cerebrovascular accident ( CVA ) ( ≤ 6 month treatment start ) , myocardial infarction ( ≤ 6 month treatment start ) , unstable angina , NYHA ≥ grade 2 chronic heart failure ( CHF ) , uncontrolled arrhythmia ; Fertile woman ( &lt; 2 year last menstruation ) men childbearing potential willing use effective mean contraception ; Subject pregnant breast feeding , plan become pregnant within 6 month end treatment ; History interstitial lung disease e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>RAS Wild-Type</keyword>
	<keyword>BRAF Wild-Type</keyword>
</DOC>